Drug Profile
Research programme: anti-inflammatory cannabinoids - Syntara Limited
Alternative Names: PXS 2000; PXS 2030; PXS 2076Latest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Pharmaxis
- Developer Syntara Limited
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor agonists; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis; Rheumatoid arthritis